WHAT IS CLAIMED IS:

1. A compound of the formula:

wherein R_1 , R_2 , R_3 , R_4 , R_5 and R_6 are each chemical residues.

- 2. The compound of Claim 1, wherein $\ensuremath{R_1}$ and $\ensuremath{R_2}$ are hydrogen.
- 3. The compound of Claim 1, wherein R_1 and R_2 are alkyl groups selected from the group consisting of straight chains, branched and cyclic alkyl groups.
- 4. The compound of Claim 3, wherein $\ensuremath{R_1}$ and $\ensuremath{R_2}$ each contain one to thirteen carbons.
- 5. The compound of Claim 4, wherein the R_1 and R_2 groups are substituted with amine groups selected from the group consisting of primary, secondary, tertiary and quaternary amines.

- 6. The compound of Claim 5, wherein the amine group substitution is on a terminal carbon.
- 7. The compound of Claim 1, wherein R_5 is a halogen selected from the group consisting of fluorine, chlorine and bromine.
- 8. The compound of Claim 1, wherein R_6 is an alkyl alcohol group selected from the group consisting of methyl alcohol, ethyl alcohol, isopropyl alcohol and n-propyl alcohol.
- 9. The compound of Claim 1, wherein R_6 is a N-alkylcarboxamido group selected from the group consisting of N-methylcarboxamido, N-ethylcarboxamido, N-isopropylcarboxamido, and N-n-propylcarboxamido.
 - 10. A compound of the formula:

$$R_{6}$$
 N
 N
 R_{4}
 R_{3}
 R_{1}
 R_{2}

 R_3 , R_4 , and R_5 are each hydrogen;

and R_6 is:

11. A pharmaceutical composition for treating hypertension in a mammal comprising:

an effective amount of the compound according to Claim 1 and a pharmaceutically acceptable carrier to the mammal in need thereof.

12. A pharmaceutical composition for treating acute ischemia in a mammal comprising:

an effective amount of the compound according to Claim 1 and a pharmaceutically acceptable carrier to the mammal in need thereof.

- 13. The pharmaceutical composition of Claim 12 wherein treating includes prophylactic effects.
- 14. A pharmaceutical composition for producing controlled vasodilation in a mammal comprising:

an effective amount of the compound according to Claim 1 and a pharmaceutically acceptable carrier to the mammal in need thereof.

15. A pharmaceutical composition for use as a sympathetic blocking agent comprising:

an effective amount of the compound according to Claim 1 and a pharmaceutically acceptable carrier to the mammal in need thereof.

- 16. A pharmaceutical composition containing an adenosine analogue that lowers blood pressure while not causing clinically relevant changes in heart rate.
- 17. A method for treating hypertension in a mammal comprising:

administering an effective amount of the compound of Claim 1 and a pharmaceutical carrier to the mammal in need thereof.

18. A method for controlling vasodilation in a mammal comprising:

administering an effective amount of the compound of Claim 1 and a pharmaceutical carrier to the mammal in need thereof.

- 19. The method of Claim 18, wherein the risk of cardiovascular events is reduced.
- 20. A method for identifying areas of cardiac infarct in a patient comprising:

administering an effective amount of the compound of Claim 1 such that the area of cardiac infarct is detectable upon imaging.